Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (253)	9/5/2000 12:52:17 PM
From: Jim Oravetz	Respond to of 7143

HELIUM KEEPS FLOWING into health and biotechnology funds. On average, the funds are returning 50.11% for the year, rising 3.75% just in the week ending Aug. 31, according to Lipper. The sector has been on an upswing since March, when it faltered in response to doubts about whether the discoveries from the Human Genome Project research could be patented. Year-to-date, the Dow Jones Biotechnology Index is up 46.86%. "We're on fire again," says Dr. Faraz Naqvi, manager of the $770 million Dresdner RCM Biotechnology fund (DRBNX), which has returned 107.8% so far this year. These stocks tend to move in line with the Nasdaq, observes Naqvi, who also believes that investors are beginning to favor biotech over pharmaceuticals. smartmoney.com Jim

To: Mark Bong who wrote (253)	9/6/2000 7:33:49 AM
From: SnowShredder	Respond to of 7143

ARIA, NEXL, & INCR ceo talks about stem cells... cnetinvestor.com Executives From Nexell Therapeutics, Ariad Pharmaceuticals and 9/6/00 3:45:00 AM Source: PR Newswire Incara Pharmaceuticals Get to the Root of Stem Cells on 'BioTalk' Radio ROSEVILLE, Calif., Sept. 6 /PRNewswire/ -- Stem cell stocks on Wall Street sprang to life in recent weeks and today's BioTalk radio program examines the opportunities and hazards of investing in this fascinating sector. Plan to get under the industry's skin with executives from three companies prominent in the space -- Dr. Harvey Berger; Chairman/CEO of Ariad Pharmaceuticals (Nasdaq: ARIA); William Albright Jr., President/COO of Nexell Therapeutics (Nasdaq: NEXL); and Clayton Duncan, President/CEO of Incara Pharmaceuticals (Nasdaq: INCR). Listeners can access today's program from 11 a.m.-noon EDT at www.informedinvestors.com or www.broadcast.com/shows/biotech, or via analog dial at WMET 1150 AM in Gaithersburg, MD. Also, join the "virtual call-in" by emailing questions in real-time during the show to co-host Tim Quast at tim@informedinvestors.com. Stem cells -- the cell from which all other cells are derived -- appear early in an embryo's development and can grow to become organs, nerves and bone marrow cells, for example. Research is controversial because it can involve the destruction of human embryos. New National Institutes of Health (NIH) guidelines to repeal a ban on federal funding of research on embryotic stem cells have dramatically affected stock prices of companies that may benefit from the changed NIH position. Dr. Berger of Ariad will discuss the ARGENT(TM) system that is the first able to deliver genes to a therapeutically relevant number of stem cells. Ariad is a leader in the discovery and development of gene therapy, cell therapy, stem cell therapy and protein therapy products featuring dose-dependent regulation by small-molecule drugs, as well as small-molecule inhibitors of signal transduction. Nexell's Albright will explain how the company utilizes cell selection technology in cell therapy for cancer and other life-threatening diseases. Incara's Duncan will discuss three current programs, including liver precursor cell therapy for the treatment of liver failure, small molecule catalytic antioxidants for treatment of stroke and chronic bronchitis, and an ultra-low molecular weight heparin for the treatment of inflammatory bowel disease. InformedInvestors.com is the conduit for unfiltered communication between individual investors and the executives of technology and biotechnology companies. Live virtual and onsite Forums, special webcasts, original editorial pieces and weekly radio shows help put individual investors in the analyst's chair. SOURCE InformedInvestors.com